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Increased expression of membrane-associated 
phospholipase A, in the lower respiratory tract of 
asymptomatic cigarette smokers 
J.-I. YAMASHITA*$, M. OGAWA* AND T. SHIRAKUSA~ 
*Department of Surgery II, Kumamoto University School of Medicine, Kumamoto, and TDepartment of 
Surgery II, Fukuoka University School of Medicine, Fukuoka, Japan 
Group II phospholipase A, (membrane-associated phospholipase AZ, M-PLA,) hydrolyses the 2-acyl position 
of a glycerophospholipid. The concentrations of M-PLA, in serum and bronchoalveolar lavage fluid (BALF) 
were measured in 13 asymptomatic cigarette smokers without clinically detectable lung disease, and the results 
were compared with those in 13 healthy non-smokers, using a specific radioimmunoassay. In addition, 
Northern blot analysis of M-PLA, mRNA was performed in preparations of total RNA extracted from 
the cell pellet of BALF from two smokers and two non-smokers. No significant difference was found in 
serum M-PLA, levels between 13 smokers (mean ?Z SD, 3.48 & 1.21 ng ml-‘) and 13 non-smokers (3.12 * 
1.06 ng ml ~ ‘). The smokers’ BALFs contained significantly greater levels of M-PLA, compared with the 
non-smokers’, whether expressed in terms of BALF volume (0.59 f 0.34 vs. 0.12 -rt 0.09 ng ml ~ ‘, WO.001) or 
protein content (7.22 f 3.17 vs. 2.31 =t 1.48 ng mg- i protein, WO.001). Northern analysis showed that the 
levels of M-PLA, mRNA in two smokers were greater than those in two non-smokers. Thus, cigarette 
smoking was associated with increased levels of M-PLA, in BALF. This enzyme may be involved in the 
pathogenesis of pulmonary disease associated with cigarette smoking. 
Introduction 
Phospholipase A, (PLA,) is a lipolytic enzyme that 
specifically hydrolyses the sn2-acyl position of a 
glycerophospholipid (1). There are two structurally 
different forms of PLA,: Groups I and II (2). Group 
I PLA, is the pancreatic form (P-PLA,) and is 
abundant in pancreatic secretions. Group II PLA, 
was initially divided into two types; membrane- 
associated PLA, (M-PLA,) and secretory PLA,. The 
former is thought to participate in regulating intra- 
cellular metabolic processes, whereas the latter is 
secreted into interstitial, intra-articular, and intra- 
vascular spaces in various inflammatory responses 
(1). However, recent studies have revealed that the 
nucleotide sequences of M-PLA, and secretory PLA, 
are identical (3,4). Group I PLA, has been investi- 
gated by many researchers in relation to several 
diseases, such as acute pancreatitis, but little is 
known about the pathophysiological role of Group II 
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PLA,, despite the presence of this form in a variety of 
mammalian cells (5-7). 
Dipalmitoylphosphatidylcholine, the major lipid 
constituent of pulmonary surfactant (8) is a sub- 
strate of PLA, (1). Several investigators have 
reported that thin layer chromatography of pulmon- 
ary surfactant recovered by bronchoalveolar lavage 
in patients with adult respiratory distress syndrome 
(9), as well as in experimental shock lung in rats (lo), 
showed a relative decrease in dipalmitoylphospha- 
tidylcholine with a corresponding increase in lyso- 
lecithin, a finding consistent with PLA,-induced 
degradation of pulmonary surfactant. Recently, the 
authors developed a specific radioimmunoassay for 
human M-PLA, and demonstrated that the serum 
M-PLA, concentration was elevated significantly in 
patients with various pulmonary disorders (11). Since 
cigarette smoking is associated with an increased 
risk for various lung diseases including chronic 
bronchitis, emphysema and lung cancer, the above 
observations prompted investigation of the concen- 
trations of M-PLA, in serum and bronchoalveolar 
lavage fluid (BALF) in asymptomatic cigarette 
smokers without clinically detectable lung disease, 
for comparison with concentrations in healthy 
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Table I Clinical characteristics of study population 
Smokers Non-smokers 
(?I= 13) (n=13) 
Age (years) 55.5 + 16.1 61.5 k 10.3 
Sex (M/F) 1013 8/5 
Smoking history 465 zk 202 0 
(cigarettes per day x years) 
Pulmonary function 
vc CL) 4.24 + 1.41 3.98 i 1.12 
FVC (“/ of predicted) 99.4 f 20.6 95.1 f 13.3 
FEV, (% of predicted) 85.2 f 5.5 85.5 f 4.3 
VC, vital capacity; FVC, forced vital capacity; FEV,, forced 
expiratory volume in 1 s. Differences between characteristics 
of smokers vs. non-smokers were not statistically significant 
(t-test). 
non-smokers. This study may suggest a role for 
M-PLA, in the development of certain cigarette- 
associated pulmonary diseases. 
Subjects and Methods 
SUBJECTS 
Bronchoalveolar lavage fluid was collected from 26 
healthy volunteers; 13 current smokers and 13 people 
who had never smoked (control group). A detailed 
smoking history was obtained from all subjects. 
These subjects had no respiratory symptoms, normal 
chest radiographs and normal spirometric test results 
(Table 1). Informed consent was obtained from each 
subject and this study was performed in accordance 
with the Declaration of Helsinki. 
BRONCHOALVEOLAR LAVAGE FLUID 
Bronchoalveolar lavage fluid was collected and as- 
sessed according to the method of Watters et al. (12). 
Briefly, BAL was performed with a flexible fibre- 
optic bronchoscope (Model BRO-YL2, Fujinon, 
Tokyo, Japan), after intramuscular pre-medication 
with atropine (0.5 mg) and pethidine (50 mg). Topical 
anaesthesia was performed with nebulized 4% lido- 
Caine to the pharynx and 2% lidocaine to the trachea 
and bronchi. After inspection of the segmental ori- 
fices, the tip of the bronchoscope was wedged into a 
subsegment of the right middle lobe. Sterile normal 
saline was instilled through the bronchoscope in 
50-ml aliquots to a total of 150 ml, with harvest of the 
fluid by immediate gentle hand suction applied 
to each instilling syringe. The recovered BALF was 
filtered through sterile gauze and centrifuged im- 
mediately at 8OOg for 10min. The protein concen- 
tration of the supernatant was determined by the 
method of Smith et al. (13) using bicinchonic acid 
with bovine serum albumin as a standard. For the 
M-PLA, determination, the supernatant was concen- 
trated using Centricon- (Grace Japan Co., Inc., 
Tokyo, Japan), whose selective molecular weight is 
10 000 (the molecular weight of M-PLA, of M-PLA, 
is 14 000). The percentage recovery of exogenous 
M-PLA, in this method was 95.1 & 2.8% (mean f 
SD). The concentrated sample was stored until the 
determination of the immunoreactive M-PLA,. Re- 
sults were expressed in ng ml - ’ BALF or ng mg ~ ’ 
protein. Differential cell counts were performed 
on the cell pellet resuspension using May-Giemsa 
staining. 
ASSAY FOR M-PLA2 
The M-PLA, concentration in serum and BALF 
from each subject was measured by a radioimmuno- 
assay using anti-M-PLA, monoclonal antibody as 
described previously (11). There is no cross-reactivity 
of this antibody with human group I PLA,, pancre- 
atic trypsin, chymotrypsin, elastase 1 and pancreatic 
secretory trypsin inhibitor (11). The detection limit of 
M-PLA, is 0.78 ng ml - ‘. The intra-assay coefficients 
of variation for the high, middle and low levels of 
BALF were 2.5, 3.4 and 6.6%, respectively. 
NORTHERN BLOT ANALYSIS 
Northern analysis of M-PLA, mRNA in prepar- 
ations of total RNA were conducted as described 
previously (14). Briefly, total RNA was extracted 
from the cell pellet of BALF from two smokers and 
two non-smokers by the guanidine thiocyanate- 
caesium chloride procedure (15). Total RNA 
(5 pug lane - ‘) was separated by 1% agarose- 
formaldehyde gels, and transferred to nylon mem- 
brane (Hybond N’) by Northern blotting. The blots 
were hybridized with 32P-labelled specific probes. The 
336 bp NcoI-ScaI fragment of Group II PLA, cDNA 
(4) was used for its mRNA detection. Filters were 
washed in 0.2 x SSC and 0.1% SDS at 65°C. As a 
control, filters were stripped and rehybridized with a 
probe for p-actin. 
STATISTICAL ANALYSIS 
Data were expressed as mean=sD. The statistical 
significance of differences in data between smokers 
and non-smokers was tested by Student’s t-test. 
P values below 0.05 were regarded as statistically 
significant. 
Results 
SERUM M-PLA, CONCENTRATION 
Immunoreactive M-PLA, in serum was detectable 
in all smokers and non-smokers, the concentration 
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Table 2 Laboratory findings in bronchoalveolar lavage fluid in study population 
Smokers Non-smokers 
(rz= 13) (n= 13) t-test 
Fluid (%) recovery 40.5 26 10.2 47.8 * 15.1 n.s. 
Total cells ( x lo5 ml ‘) 2.9 f 1.8 1.8 * 1.0 ns. 
Macrophages (%) 91.5 f 3.5 88.9 & 4.1 ns. 
Neutrophils (%) 1.8 f 1.3 1.1 * 0.9 n.s. 
Eosinophils (%) 0.8 It 1.1 0.5 f 0.7 n.s. 
Lymphocytes (“‘%) 5.9 + 3.5 9.5 f 5.6 n.s. 
CD4’/CD8+ cells 1.51 & 1.24 1.85 f 1.41 n.s. 
Total protein (mg ml - ‘) 0,077 * 0.071 0,059 h 0.042 ns. 
ir-M-PLA, (ng ml - i), 0.59 3r 0.34 0.12 * 0.09 P<O.OOl 
Mean f SD (range) (0.1 l-3.24) (0.006-0.65) 
ir-M-PLA, (ng mg- ’ protein), 7.22 f 3.17 2.31 f 1.48 P<O,OOl 
Mean f SD (range) (1.32-36.5) (0.114-8.24) 
ir-M-PLA,, immunoreactive membrane-associated phospholipase A2; n.s., not significant. 
ranging from 1.5 to 5.2 ng ml- ‘. No significant 
differences were found in M-PLA, levels between 
smokers (mean f SD: 3 48 & 1.21 ng ml ~ ‘) and 
non-smokers (3.12 * 1.06 ng ml- ‘). 
M-PLA2 CONCENTRATION IN BALF 
M-PLA, concentration in BALF was measured in 
the same radioimmunoassay. Table 2 shows BALF 
test results. There were no significant differences in 
the fluid recovery rate, total cell count, cellular 
constituents or total protein levels. Immunoreactive 
M-PLA, was detectable in the concentrated BALF of 
all smokers and non-smokers. The range of the 
standard curve is 0.78-50 ng ml - r and the actual 
concentrations measured in the concentrated fluid 
(150 times concentrated at maximum) were within 
the range. In the smokers, M-PLA, levels ranged 
from 0.11 to 3.24 ng ml - *, and in the non-smokers, 
M-PLA, levels ranged from 0.006 to 0.65 ng ml- r. 
The mean concentration of M-PLA, was 4.9-fold 
greater in the BALF of smokers (mean rt SD: 0.59 f 
0.34 ng ml - ‘) vs. non-smokers (0.12 & 0.09 ng ml - ‘) 
(P<O.OOl). When M-PLA, levels were expressed as 
w w - ’ of protein, the significant difference between 
smokers and non-smokers persisted (7.22 rt 3.17 VS. 
2.31 + 1.48, P<O.OOl), indicating that the differences 
between smokers and non-smokers were not due to 
leakage of non-specific protein into the airways. 
M-PLA, mRNA EXPRESSION 
To examine whether M-PLA, mRNA expression is 
also increased in smokers, Northern blot analysis of 
total RNA was performed in four BALF cell pellets. 
Immunoreactive M-PLAz levels in BALF of the 
four subjects were as follows: Case 1 (smoker), 
Plate I Northern blot analysis of total RNA from 
Case no. 
1 2 3 4 
M-PLA2 
O-actin 
bronchoalveolar lavage fluid constituents. Total RNA was 
hybridized with human group II PLA, cDNA as probe. To 
assess equal load of mRNA per lane, the filter was sub- 
sequently hybridized to a p-actin probe. Cases 1 and 3, 
smokers; Cases 2 and 4, non-smokers. 
36.5 ng mg- ’ protein; Case 2 (non-smoker), 
0.114ngmgg’ protein; Case 3 (smoker), 
21.2ngmgg’ protein; and Case 4 (non-smoker), 
0.34 ng mg- r protein. Using a radiolabelled 
M-PLA, cDNA probe, M-PLA, mRNA was 
clearly demonstrated in total RNA preparations 
from all subjects. The levels of M-PLA, mRNA 
in two smokers were greater than those in two 
non-smokers (Plate 1). 
Discussion 
The authors showed that BALF from asympto- 
matic cigarette smokers contained significantly 
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greater amounts of M-PLA, than that of non- 
smokers, whereas the M-PLA, levels in serum did 
not differ between smokers and non-smokers. In 
addition, Northern blot analysis showed the 
increased expression of M-PLA, mRNA in BALF, 
suggesting that cigarette smoking is associated with 
increased levels of M-PLA, in the lower respiratory 
tract. Although the origin of increased M-PLA, in 
the respiratory tract of cigarette smokers was 
unclear, a likely source is the alveolar macrophages, 
since alveolar macrophages reportedly contain 
M-PLA, (16). In the authors’ separate investigation, 
immunohistochemical staining of M-PLA, using 
open lung biopsy specimens from patients with 
eosinophilic granuloma of the lung, known to be 
associated with an abnormal response to cigarette 
smoking (17,18), revealed intense staining of this 
enzyme in alveolar resident cells (unpubl. data). 
The meaning of increased expression of M-PLA, 
in BALF of smokers is unknown. However, it is 
possible that M-PLA, may be involved in the patho- 
genesis of cigarette-smoking-associated pulmonary 
diseases. Seilhamer et al. (19) suggested that M-PLA, 
is secreted as an active enzyme because no pro- 
enzyme segment was evident in the upstream region 
of the mature peptide. In animal models, locally 
produced or activated M-PLA, induced the degrada- 
tion of pulmonary surfactant to cause respiratory 
disorders resembling adult respiratory distress syn- 
drome (20). Increased M-PLA, activity recovered by 
BAL was demonstrated in experimental asbestosis in 
sheep (21) and guinea pigs (22), and in patients with 
asthma and alveolar proteinosis (23). 
Recently, the authors demonstrated that human 
M-PLA, itself has a mitogenic effect on fibroblasts 
(24), and that this enzyme may play a paracrine role 
in the progression of several diseases (10,25). 
M-PLA, augments the production of prostaglandin 
E, at the local site, which is known to inhibit the host 
immunological response (26). In addition, the gener- 
ation of biologically active free fatty acids and lyso- 
phosphatides may also influence cellular and organ 
system function profoundly (27, 28). However, none 
of these relates directly to pathogenesis of lung 
diseases known to be induced by cigarette smoking. 
In addition, there was no relationship between the 
elevation of M-PLA, concentrations and the amount 
or duration of cigarette smoking in this study. Future 
studies are necessary to clarify a possible link 
between elevated M-PLA, and smoking-induced lung 
disease. 
In conclusion, BALF from asymptomatic cigarette 
smokers contained a significantly greater amount of 
M-PLA, compared with that from non-smokers. If 
increased levels of M-PLA, prove to be an import- 
ant link between smoking and lung disease, manipu- 
lation of this enzyme system may become a rational 
therapeutic approach. 
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